← Studies & programmes
Emerging treatmentsPhase 3 study in peopleEU authorised

Briumvi (ublituximab): EU-authorised infusion treatment for active relapsing MS

EU-authorised indication: Adult patients with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features

Published by MyelinWatch:

Briumvi (ublituximab) · Ublituximab is a laboratory-made antibody that attaches to CD20, a marker on B cells, a type of white blood cell involved in MS inflammation, and removes many of these cells. Briumvi is given as an infusion into a vein: 150 mg first, 450 mg two weeks later, then 450 mg every 24 weeks. Before each infusion, people receive a corticosteroid and an antihistamine to reduce infusion reactions. The two Phase 3 ULTIMATE studies compared it with teriflunomide, an MS medicine taken by mouth.

What is being studied

Ublituximab is a laboratory-made antibody that attaches to CD20, a marker on B cells, a type of white blood cell involved in MS inflammation, and removes many of these cells. Briumvi is given as an infusion into a vein: 150 mg first, 450 mg two weeks later, then 450 mg every 24 weeks. Before each infusion, people receive a corticosteroid and an antihistamine to reduce infusion reactions. The two Phase 3 ULTIMATE studies compared it with teriflunomide, an MS medicine taken by mouth.

Research stage

Phase 3 study in people

EU-authorised for adults with relapsing MS with active disease; ULTIMATE I and II completed

What we know so far

The EU authorised Briumvi on 31 May 2023 for adults with relapsing forms of MS with active disease, shown by relapses or MRI findings; in the United States it was approved on 28 December 2022. The two identical 96-week ULTIMATE studies enrolled 1,094 people. The yearly relapse rate was 0.08 with ublituximab versus 0.19 with teriflunomide in ULTIMATE I and 0.09 versus 0.18 in ULTIMATE II, and there were fewer active inflammatory lesions on MRI. Disability worsening confirmed after 12 weeks did not differ significantly (5.2% versus 5.9% in the pooled analysis). Infusion-related reactions occurred in 47.7% of people on ublituximab, and serious infections in 5.0% versus 2.9% with teriflunomide; the EU product information says infusion reactions were most frequent with the first infusion. The EU product information requires hepatitis B screening before treatment and warns about infections, including hepatitis B reactivation and PML, a rare brain infection seen very rarely with anti-CD20 antibodies. The US prescribing information, revised in January 2026, also warns of liver injury and requires liver tests before the first dose.

What this means for patients today

Briumvi is an authorised medicine, not an experimental one, but only for adults with relapsing MS with active disease. It is not authorised for children, the studies did not show a significant effect on disability worsening, and it is not evidence of myelin repair. The cited sources do not establish whether Briumvi is available or reimbursed in Greece. The ULTIMATE studies compared it only with teriflunomide, so they do not show how it compares with other anti-CD20 medicines. Further TG Therapeutics studies of a modified dosing schedule, injections under the skin and use in children are accepting participants; none lists a site in Greece. Treatment decisions belong with a neurologist experienced in MS.

Treatment or approach
Briumvi (ublituximab) • intravenous anti-CD20 antibody authorised in the EU for adults with relapsing MS with active disease
How it is intended to work
Anti-CD20 B-cell depletion by intravenous ublituximab
Where the study is running
EU-wide authorisation; Greek availability or reimbursement is not established by the cited sources
Source: European Medicines Agency — official EMA medicine record ↗Source: EMA — Briumvi product information (summary of product characteristics) ↗ Source: New England Journal of Medicine — ULTIMATE I and II trials, PMID 36001711 ↗ Source: ClinicalTrials.gov — ULTIMATE I NCT03277261, completed with results posted ↗ Source: ClinicalTrials.gov — ULTIMATE II NCT03277248, completed with results posted ↗ Source: US FDA, Drugs@FDA — Briumvi BLA 761238, approved 28 December 2022 ↗ Source: TG Therapeutics — US prescribing information for Briumvi, revised January 2026 ↗ Source: ClinicalTrials.gov — ENHANCE NCT05877963, modified dosing schedule, accepting participants ↗ Source: ClinicalTrials.gov — NCT07503873, injections under the skin, accepting participants ↗ Source: ClinicalTrials.gov — NCT07220252, children aged 10 to 17, accepting participants ↗
Published by MyelinWatch
Last substantive MyelinWatch update